The value of 18F-FDG PET/CT imaging in predicting the efficacy of PD-1/PD-L1 immune checkpoint inhibitors in advanced non-small cell lung cancer
Among patients with advanced NSCLC who received PD-1/PD-L1 ICIs in combination or without chemotherapy, MTVwb was an independent influencing factor for DCB, PFS, and OS. The treatment modality is also an independent influencing factor for DCB and PFS. <sup>18</sup>F-FDG PET/CT has a very promising application prospect in predicting the prognosis of patients treated with immune checkpoint inhibitors. At the same time, the level of sugar metabolism is positively correlated with PD-L1 expression.
Authors
- Wen Zhou (ORCID: https://orcid.org/0000-0003-4085-7714)
- Huiwen Luo (ORCID: https://orcid.org/0000-0003-3626-6233)
- Jian Wang (ORCID: https://orcid.org/0000-0002-9286-2809)
- Xiaofeng Li (ORCID: https://orcid.org/0000-0001-7038-5119)
- Lin Li (ORCID: https://orcid.org/0000-0002-8014-8296)
- Dong Dai (ORCID: https://orcid.org/0000-0003-1278-5581)
- Wengui Xu
- Xuefeng Hou
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Tianjin Children's Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fonc.2025.1651843
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00